| News for the PBM Industry |  |
| Featured Stories |  |  |
|
- PCMA: State biosimilar laws will raise costs
Enacting laws at the state level that would restrict the substitution of biosimilar drugs would raise costs for patients and employers and compete with forthcoming federal laws, the Pharmaceutical Care Management Association says. "Creating a patchwork of dueling state and federal rules would make it harder for pharmacists to know when they can dispense a biosimilar," according to PCMA. "That would raise costs for patients and their employers, who typically cover two-thirds of prescription drug benefit costs." AIS Health/Specialty Pharmacy News
(2/8)
| Legislative & Regulatory News |  |  |
|
| PBM Industry News |  |  |
|
| Drug Industry Spotlight |  |  |
|
| SmartQuote |  |  |
|
 | The only man I know who behaves sensibly is my tailor; he takes my measurements anew each time he sees me. ... The rest go on with their old measurements and expect me to fit them."
--George Bernard Shaw, Irish playwright

|
| |
| |
|
| |
| About PCMA |
|
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 210 million Americans with health coverage provided through Fortune
500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.
|
|
| |
| | Recent PCMA SmartBrief Issues:
- Friday, February 08, 2013
- Thursday, February 07, 2013
- Wednesday, February 06, 2013
- Tuesday, February 05, 2013
- Monday, February 04, 2013
| | | Lead Editor: Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | |
| |
|
| © 1999-2013 SmartBrief, Inc.® Legal Information |
|